Journal article icon

Journal article

Barriers to routine G6PD testing prior to treatment with primaquine.

Abstract:

Background

Primaquine is essential for the radical cure of vivax malaria, however its broad application is hindered by the risk of drug-induced haemolysis in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. Rapid diagnostic tests capable of diagnosing G6PD deficiency are now available, but these are not used widely.

Methods

A series of qualitative interviews were conducted with policy makers and healthcare providers in four vivax-endemic count...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More from this funder
Name:
Wellcome Trust
Grant:
200909
More from this funder
Name:
US President’s Malaria Initiative
More from this funder
Name:
Bill and Melinda Gates Foundation
More from this funder
Name:
ustralian Government Department of Foreign Affairs and Trade
Publisher:
BioMed Central
Journal:
Malaria Journal More from this journal
Volume:
16
Issue:
1
Pages:
329
Publication date:
2017-08-01
Acceptance date:
2017-08-07
DOI:
EISSN:
1475-2875
Pmid:
28797255
Language:
English
Keywords:
Pubs id:
pubs:724233
UUID:
uuid:688c5ba2-7a05-4127-8a77-fd9d4dd44166
Local pid:
pubs:724233
Source identifiers:
724233
Deposit date:
2017-08-25

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP